These stocks are usually going up or down because of brokers upgraded or downgraded .If you are looking to day trade, you might want to check out the following stocks. I usually throw these on my watch list and monitor with resistance & support levels.You can also check previous stocks to buy reports- Right Here.
Akamai (AKAM), IPC The Hospitalist Co. (IPCM), El Paso Electric (EE), Avago (AVGO) , Merck (MRK), Impax (IPXL), Concur Technologies (CNQR) were upgraded or downgraded by analysts.
Akamai (AKAM), IPC The Hospitalist Co. (IPCM), El Paso Electric (EE), Avago (AVGO) , Merck (MRK), Impax (IPXL), Concur Technologies (CNQR) were upgraded or downgraded by analysts.
Akamai (AKAM) upgraded to Hold from Underperform at Jefferies.Citigroup upgraded Akamai citing ecommerce seasonality and easy comps in the first half of 2012. The firm raised its price target for shares to $36 from $21. Note shares of Akamai were downgraded to Sell this morning at Citigroup.
IPC The Hospitalist Co. (IPCM) downgraded to Hold from Buy at Jefferies.Jefferies downgraded IPC The Hospitalist Co. citing a lack of earnings visibility after the company reduced its FY11 outlook. The firm lowered its price target for shares to $40 from $50.
El Paso Electric (EE) upgraded to Hold from Underperform at Jefferies.Jefferies upgraded El Paso Electric citing valuation and raised its price target for shares to $34.50 from $28.
Avago (AVGO) upgraded to Buy from Neutral at Nomura.Nomura upgraded Avago based on valuation and underestimated growth potential in wireless handsets. Price target raised to $35 from $30.
Merck (MRK) downgraded to Hold from Buy at Jefferies.Jefferies downgraded Merck based on valuation. Price target raised to $40 from $37.
Impax (IPXL) upgraded to Buy from Hold at Canaccord.Canaccord upgraded Impax based on low consensus estimates, progress on FDA issues, an under-estimated pipeline, and expected IPX-066 product approval. Price target raised to $28 from $21.
Concur Technologies (CNQR) downgraded to Hold from Buy at Jefferies Jefferies downgraded Concur Technologies citing valuation and less upside potential to estimates. The firm keeps a $53 price target for shares.
Impax (IPXL) upgraded to Buy from Hold at Canaccord.Canaccord upgraded Impax based on low consensus estimates, progress on FDA issues, an under-estimated pipeline, and expected IPX-066 product approval. Price target raised to $28 from $21.
Concur Technologies (CNQR) downgraded to Hold from Buy at Jefferies Jefferies downgraded Concur Technologies citing valuation and less upside potential to estimates. The firm keeps a $53 price target for shares.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
